Encouraged by preliminary findings that an antilymphoma vaccine has a clear antitumor effect, the National Cancer Institute (NCI) is planning a large phase 3 clinical trial of the experimental vaccine. The vaccine, which is derived from a patient's own cancer cells, is intended to prevent recurrences of the disease.
The study, published in the October Nature Medicine, involved 20 patients with follicular lymphoma who had achieved a complete clinical response after chemotherapy. The patients were then given a vaccine formulated with tumor-associated antigens (from their own tumor cells) and granulocyte-monocyte colony-stimulating factor (used as an immune adjuvant).
Stephenson J. Lymphoma Vaccine. JAMA. 1999;282(19):1805. doi:10.1001/jama.282.19.1805-JHA90009-2-1